SCHEMBL3396336

SCHEMBL3396336

COc1ccc(OC)c(Cn2ncc3c(Cl)nc(N)nc32)c1

nearest known ligand 0.61

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 5/20 0.61
HSP90AB1 P08238 3/20 0.61
TRAP1 Q12931 4/20 0.55
HSP90B1 P14625 1/20 0.51
ADA P00813 1/20 0.46
ADORA2A P29274 1/20 0.46
ADORA1 P30542 1/20 0.46
EGFR P00533 1/20 0.44
DHFR P00374 6/20 0.43
NPBWR1 P48145 3/20 0.43
IDO1 P14902 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20118816 0.89 HSP90AA1 (0.60) HSP90AA1HSP90AB1TRAP1HSP90B1ADA
SCHEMBL10195525 0.83 HSP90AA1 (0.60) HSP90AA1HSP90AB1TRAP1HSP90B1ADA
SCHEMBL3391551 0.81 HSP90AA1 (0.68) HSP90AA1HSP90AB1EGFRDHFR
SCHEMBL4455658 0.81 ADORA2A (0.67) HSP90AA1HSP90AB1TRAP1HSP90B1ADA
SCHEMBL3392701 0.80 HSP90AB1 (0.67) HSP90AA1HSP90AB1ADORA2AADORA1EGFR
SCHEMBL3394188 0.80 HSP90AA1 (0.62) HSP90AA1HSP90AB1TRAP1HSP90B1ADORA2A
SCHEMBL20118748 0.79 TRAP1 (0.56) HSP90AA1HSP90AB1TRAP1HSP90B1ADA
SCHEMBL14568299 0.78 HSP90AA1 (0.61) HSP90AA1HSP90AB1TRAP1HSP90B1ADORA2A
SCHEMBL14568297 0.78 HSP90AA1 (0.63) HSP90AA1HSP90AB1TRAP1HSP90B1NPBWR1
SCHEMBL3396772 0.78 HSP90AA1 (0.61) HSP90AA1HSP90AB1TRAP1HSP90B1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2145888-A1 Deazapurine derivatives as HSP90-Inhibitors Conforma Therapeutics Corporation (US) 2010-01-20 EP disclosed
US-20070111996-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2007-05-17 US disclosed
US-7148228-B2 Pyrazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION (US) 2006-12-12 US disclosed
EP-1670802-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS Conforma Therapeutic Corporation (US) 2006-06-21 EP disclosed
EP-1615921-A2 PYRIDO 2,3-D PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-01-18 EP disclosed
US-20050119282-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors CONFORMA THERAPEUTICS CORPORATION 2005-06-02 US disclosed
WO-2005028434-A2 NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS CONFORMA THERAPEUTICS CORPORATION (US) 2005-03-31 WO disclosed
WO-2004085436-A2 PYRIDO[2,3-D]PYRIMIDIN-7-CARBOXYLIC ACID DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2004-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119282-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors HSP90AB2P, HSP90AB1, HSP90AA1 HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 9/4885
US-20070111996-A1 Pyrazolopyrimidines and related analogs as HSP90-inhibitors HSP90AB2P, HSP90AB1, HSP90AA1 HSP90AA1 3/4885HSP90AB1 2/4885TRAP1 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.